SCHEMBL6808152

SCHEMBL6808152

[CH2]COP(=O)(OC(C)(C)C)OC(C)(C)C

nearest known ligand 0.32

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22772619 0.81 CYP3A4 (0.34) TSHR
SCHEMBL3816214 0.77 TSHR (0.60) TSHR
SCHEMBL17999714 0.75 CYP2C19 (0.33) TSHR
SCHEMBL194036 0.75 ALDH1A1 (0.35) TSHR
SCHEMBL1486113 0.75 TSHR (0.32) TSHR
SCHEMBL29248196 0.75 TSHR (0.32) TSHR
SCHEMBL486485 0.74 TSHR (0.31) TSHR
SCHEMBL16072566 0.73 TSHR (0.31) TSHR
SCHEMBL3815405 0.73 CYP3A4 (0.46) TSHR
SCHEMBL21749625 0.73 TSHR (0.31) TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040067994-A1 BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS PAGET STEVEN D (US) 2004-04-08 US claimed
US-6608081-B2 Treating pneumonia ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-08-19 US claimed
US-20020161029-A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-10-31 US claimed
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED 2023-05-25 US disclosed
EP-4126863-A1 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) Vertex Pharmaceuticals Incorporated (US) 2023-02-08 EP disclosed
WO-2021203025-A1 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed
EP-3247713-B1 PYRAZOLO[3,4-D]PYRIMIDIN DERIVATIVE AND ITS USE FOR THE TREATMENT OF LEISHMANIASIS GLAXOSMITHKLINE IP DEV LTD (GB) 2019-08-28 EP disclosed
US-10253028-B2 Pyrazolo[3,4-D]pyrimidin derivative and its use for the treatment of leishmaniasis GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-04-09 US disclosed
US-20170369496-A1 PYRAZOLO[3,4-D]PYRIMIDIN DERIVATIVE AND ITS USE FOR THE TREATMENT OF LEISHMANIASIS UNIVERSITY OF DUNDEE (GB) 2017-12-28 US disclosed
EP-3247713-A1 PYRAZOLO[3,4-D]PYRIMIDIN DERIVATIVE AND ITS USE FOR THE TREATMENT OF LEISHMANIASIS GlaxoSmithKline Intellectual Property Development Limited (GB) 2017-11-29 EP disclosed
WO-2016116563-A1 PYRAZOLO[3,4-D]PYRIMIDIN DERIVATIVE AND ITS USE FOR THE TREATMENT OF LEISHMANIASIS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2016-07-28 WO disclosed
US-6770664-B2 PYRROLO(3,4-C)PYRAZOL-5(4H)-YL)-3-FLUOROPHENYL)-2-OXO-5 -OXAZOLIDINYL)METHYL)ACETAMIDE DERIVATIVES; BACTERICIDES AGAINST DRUG RESISTANT STAPHYLOCOCCUS, STREPTOCOCCUS, AND/OR ENTEROCOCCUS PAGET STEVEN D (US) 2004-08-03 US disclosed
US-6608081-B2 Treating pneumonia ORTHO-MCNEIL PHARMACEUTICAL, INC. 2003-08-19 US disclosed
US-20020161029-A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020161029-A1 Bicyclic heterocyclic substituted phenyl oxazolidinone antibacterials, and related compositions and methods OXA1L, NDUFS3, CYCS TSHR 3826/4885
US-20040067994-A1 BICYCLIC HETEROCYCLIC SUBSTITUTED PHENYL OXAZOLIDINONE ANTIBACTERIALS, AND RELATED COMPOSITIONS AND METHODS OXA1L, NDUFS3, CYCS TSHR 3826/4885
US-20170369496-A1 PYRAZOLO[3,4-D]PYRIMIDIN DERIVATIVE AND ITS USE FOR THE TREATMENT OF LEISHMANIASIS PIR, PAH, THPO TSHR 3325/4885
US-10253028-B2 Pyrazolo[3,4-D]pyrimidin derivative and its use for the treatment of leishmaniasis PIR, PAH, THPO TSHR 3325/4885
US-20230159521-A1 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) SERPINA2, SERPINE1, SERPINA3 TSHR 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.